23 Jul, 2026
Amyotrophic lateral sclerosis, usually referred to as Lou Gehrig's disease, is a neurodegenerative condition that gradually affects the nerve cells in the central nervous system that regulate the voluntary muscles. Muscle twitching, stiffness, and weakness are common symptoms brought on by a decrease in the size of the muscles in the arms or legs. In over half of ALS patients, the capacity to swallow, breathe, speak, walk, and use one's hands may be lost. In three to five years after gradually losing their ability to breathe, people with ALS often die from respiratory failure, according to the National Institute of Neurological Disorders and Stroke (NINDS).
Most people with Lou Gehrig's disease, also known as amyotrophic lateral sclerosis (ALS), die between two and five years after being given the fatal neuromuscular diagnosis. A hereditary form of ALS accounts for 5–10% of cases, and unidentified causes account for the other issues. ALS affects people of all races and ethnicities. White people, men, non-Hispanics, those in their 60s, and those with a family history of the condition are more likely to develop it. According to a review by Longinetti that was published in October 2019 and includes a summary of epidemiologic studies that examined the incidence and risk factors for ALS and were published in the prior 18 months, an increasing incidence and prevalence of ALS are still being reported from various parts of the world.
Adults over the age of 65 are becoming more and more prevalent. According to World Population Prospects, one in six people will be over 65 by 2050, up from one in eleven today. By 2050, one in four individuals in Europe and North America may be 65 or older. In 2018, seniors 65 and over surpassed children under five worldwide for the first time. As the population ages, age-related neurological disorders such as amyotrophic lateral sclerosis (ALS), a fatal, chronic disease characterized by the degeneration of upper and lower motor neurons in the brain and spinal cord, are becoming more prevalent. As a result, as the population ages and the risk of ALS increases, the market is growing.
North America is the most significant revenue contributor and is anticipated to expand at a CAGR of 6.55% over the projection period. The American economy has experienced some of the most dramatic growth. It currently dominates a sizeable percentage of the market under consideration, and it is anticipated that this tendency will continue during the projected time. Two key variables affecting the market in the United States are the increase in the senior population and the growing patient base for Lou Gehrig's disease and amyotrophic lateral sclerosis. In 2019, there will be around 52,788,000 Americans over the age of 65, according to data from census.gov. The prevalence of neurodegenerative disorders, such as amyotrophic lateral sclerosis, is expected to increase as the nation's population ages since older people are more prone to develop them.
Asia-Pacific is anticipated to grow at a CAGR of 6.80% over the forecast period. China's market for therapies to treat amyotrophic lateral sclerosis is steadily growing. The drivers driving the market's growth in this area include the rising prevalence of ALS, the growing burden of the senior population, and the increasing number of ALS-related studies. In 2016, China's incidence rate for amyotrophic lateral sclerosis was 1.65 per 100,000 persons, and its prevalence rate was 2.91 per 100,000, according to a study titled "Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a nationwide population-based study." China is aging much faster than other countries with low and middling incomes.
sales@straitsresearch.com